This week, the overall grades of 6 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Cardiome Pharma Corp. (CRME) earns a F this week, moving down from last week’s grade of D. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.

Pulmatrix Inc (PULM) slips from a D to a F this week. For more information, get Portfolio Grader’s complete analysis of PULM stock.

Slipping from a C to a D rating, Acura Pharmaceuticals, Inc. (ACUR) takes a hit this week. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

Novogen Limited Sponsored ADR (NVGN) is having a tough week. The company’s rating falls from a C to a D. Novogen Limited Sponsored ADR is a medical services company which develops and markets pharmaceutical products in Australia. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NVGN stock.

This week, ContraVir Pharmaceuticals, Inc.’s (CTRV) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions and free cash flow. For more information, get Portfolio Grader’s complete analysis of CTRV stock.

BioPharmX Corp.’s (BPMX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BPMX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.